Top

Musa Yilmaz, MD

Department of Leukemia, Division of Cancer Medicine

About Dr. Musa Yilmaz

Dr. Musa Yilmaz received his medical training from Marmara University School of Medicine in Turkey. His residency was completed at the University of TX Medical School in Houston, TX. Dr. Yilmaz then completed fellowships in both Leukemia and Hematology/Oncology at The University of TX MD Anderson Cancer Center, and Baylor College of Medicine; also, in Houston, TX. He is currently an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center.

Dr. Musa Yilmaz has published extensively in the field of leukemia, and particularly, on prospective phase I and II trials of novel therapeutic combinations. He also serves as the Principal Investigator for four, active, clinical trials. Dr. Yilmaz’ primary, research interests have been the role of early response assessment, particularly MRD (Minimal Residual Disease), in patients with acute leukemias and how this information can be used to identify patients at highest risk for relapse and death. In particular, he has published a paper in the American Journal of Hematology on the impact of achieving early MRD negativity in patients with ALL. He has also authored several other papers on the role of MRD in acute leukemias.

Primary Appointment

Adjunct Faculty, Clinical Ethics Department, The University of Texas MD Anderson Cancer Center, Houston, Texas

Associate Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2008	Marmara University School of Medicine, Istanbul, TR, MD

Postgraduate Training

2013-2016	Clinical Fellowship, Hematology and Oncology, Baylor College of Medicine, Houston, Texas
2012-2013	Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
2009-2012	Clinical Residency, Internal Medicine, The University of Texas Medical School, Houston, Texas

Licenses & Certifications

2016	American Board of Internal Medicine Hematology
2016	American Board of Internal Medicine Oncology
2016	Texas Medical Board
2012	American Internal Medicine Board Certification
2012	ABIM Internal Medicine Certification

Experience & Service

Faculty Academic Appointments

Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2022

Administrative Appointments/Responsibilities

Inpatient Medical Director, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present

Extramural Institutional Committee Activities

Member, Data and Biospecimen Access Committee (DBAC), The University of Texas MD Anderson Cancer Center, 2022 - 2025

Member, VIZIENT Mortality Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Institutional Review Board (IRB #5), The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Human Subjects Research Informatics Subcommittee (HSRIS), The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Institutional Review Board (IRB #1), The University of Texas MD Anderson Cancer Center, 2019 - 2020

Member, Scientific Research Committee (SRC #4), The University of Texas MD Anderson Cancer Center, 2017 - 2019

Editorial Activities

Associate Editor, Frontiers in Oncology, 2023 - Present

Editorial Board Member, Hematology, 2022 - Present

Editorial Board Member, Cancers, 2022 - Present

Honors & Awards

2025 - 2026	Top 1% Provider, The University of TX MD Anderson Cancer Center
2020 - 2021	Top 1% Providers, The University of TX MD Anderson Cancer Center
2018 - 2019	Top Performer Award, The University of TX MD Anderson Cancer Center
2015	Abstract Achievement Award, American Society of Hematology
2005 - 2006	Outstanding Achievement Award, Turkish Educational Foundation
2003 - 2004	Outstanding Achievement Award, Turkish Educational Foundation

Professional Memberships

White Tulip Health Foundation

2019 - Present

Society of Hematologic Oncology (SOHO)

2016 - Present

American Society of Hematology (ASH)

2013 - Present

American Society of Clinical Oncology (ASCO)

2013 - Present

Selected Presentations & Talks

National Presentations

2026. Quizartinib in Combination with Decitabine and Venetoclax for Newly Diagnosed and Relapsed/refractory FLT3-mutated AML. Conference. American Society of Cancer Oncology (ASCO). Chicago, Illinois, US.
2025. Treating AML in 2025: Latest Developments and ASH Meeting Insights. Invited. 7th Annual ASH Review on Hematology and Immunotherapy Symposium. Lexington, KY, US.
2024. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML. Poster. American Society of Hematology (ASH).
2024. Acute Leukemia: Where Do We Stand Now?. Invited. Santa Fe Precision Oncology Symposium. Santa Fe, NM, US.
2023. Insights into FLT3 Mutated AML Treatment from Historic Milestones to Cutting-Edge Approvals. Invited. Research Town Hall Series. Houston, Texas, US.
2022. The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms. Poster. American Society of Hematology (ASH).
2022. Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML). Poster. American Society of Hematology (ASH).
2021. Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor “Triplet” Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. Invited. American Society of Hematology (ASH).
2021. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) – RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Invited. American Society of Hematology (ASH).

International Presentations

2025. Evolving Paradigms in AML: How Transplantation Fits in the Modern Therapeutic Landscape. Invited. International Congress of BMT 2025 (ICBMT). South Korea.
2025. Management of FLT3 mutated AML. Invited. Konya, TR.
2025. Phase I/II Study of Decitabine, Venetoclax, and Quizartinib Triplet Combination in FLT3-ITD Mutated AML. Conference. European Hematology Association Annual Meeting. Milan, IT.
2024. PHASE I/II STUDY OF DECITABINE, VENETOCLAX, AND QUIZARTINIB TRIPLET COMBINATION IN FLT3-ITD MUTATED AML. Poster. European Hematology Society (EHA).
2022. Acute Promyelocytic Leukemia-Preventing Complications Early in the Disease Course. Invited. Colloquium of Acute Leukemia and Myelodysplastic Syndrome Annual Conference in Mexico. Virtual, US.
2022. (Quizartinib QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial. Poster. ASCO. Zaventem, BE.
2021. "QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY Session Title: Novel insights into AML treatment". Invited. European Hematology Association (EHA).

Formal Peers

2026. Clinical Effectiveness in Leukemia-Next Steps. Houston, Texas, US.
2025. Online Post ASH Review. Houston, Texas, US.
2025. A Data-Driven Strategy for Reducing Leukemia Readmissions. Houston, Texas, US.
2024. Acute Myeloid Leukemia. San Antonio, Texas, US.
2023. FLT3 Mutations in AML. Visiting. Houston, TX, US.
2022. Treatment of FLT3 mutated AML. Houston, Texas, US.
2022. Quizartinib with Decitabine and Venetoclax (Triplet) is Active in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia-A Phase I/II Study. Houston, Texas, US.
2022. Management of FLT3 mutated AML. Houston, Texas, US.
2021. FLT3 Mutations in Acute Myeloid Leukemia. Visiting. Houston, TX, US.
2021. Targeting FLT3 mutations in Acute Myeloid Leukemia. Visiting. Houston, TX, US.
2021. Case Study Discussion: AML with monocytic differentiation vs CMML, and AML with liver involvement. Invited. Phoenix, AZ, US.
2020. Quizartinib and Decitabine +/- Venetoclax Is Highly Active in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML): Clinical Report and Signaling CYTOF profiling from a Phase IB/II Trial. Visiting. Houston, TX, US.
2020. Outcomes in FLT3+ AML Exposed to Sequential FLT3-Inhibitor Based Therapies. Visiting. Houston, TX, US.
2019. FLT3 inhibitors in newly diagnosed and relapsed AML. Visiting. Houston, TX, US.
2019. AML: Diagnosis, Treatment and Research. Invited. Albuquerque, NM, US.
2019. Acute Myeloid Leukemia. Invited. Albuquerque, NM, US.
2018. How I Treat Acute Lymphocytic Leukemia (ALL) in 2018. Invited. Tampa, FL, US.
2017. FLT3 inhibitors in AML – Focus on Quizartinib. Visiting. Houston, TX, US.

Less

Grant & Contract Support

Date:	2021 - 2021
Title:	A Phase I/II Study of Decitabine, Venetoclax and Quizartinib in Patients with FLT3-mutated Acute Myeloid Leukemia (AML)
Funding Source:	2020 ASH Scholar Award
Role:	PI
ID:	FP000011735

Date:	2020 - Present
Title:	Strategic Alliance: A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Quizartinib in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Funding Source:	Daiichi Sankyo, Inc
Role:	PI
ID:	2019-0351

Date:	2019 - Present
Title:	Strategic Alliance: A combination of cladribine, idarubicin, cytarabine (CLIA) and Quizartinib for the treatment of patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Funding Source:	Daiichi Sankyo, Inc
Role:	PI
ID:	2017-0153

Date:	2018 - Present
Title:	Strategic Alliance: A Phase II Study of Quizartinib in Combination with Decitabine for the Treatment of Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Funding Source:	Daiichi Sankyo, Inc
Role:	PI
ID:	2018-0394

Date:	2018 - Present
Title:	Clonal Evolution in Acute Myeloid Leukemia (AML): Relapse after a Long Remission Period
Funding Source:	2018 Leukemia Texas Research Grant
Role:	PI
ID:	FP00005257

Date:	2017 - Present
Title:	Clonal Evolution in Acute Myeloid Leukemia (AML): Relapse after a Long Remission Period
Funding Source:	2017 Leukemia Texas Research Grant
Role:	PI

Date:	2013 - 2021
Title:	An Open-Label Bosutinib Treatment Extension Study for Subjects with Chronic Myeloid Leukemia (CML) Who Have Previously Participated in Bosutinib Studies B1871006 or B1871008
Funding Source:	Pfizer
Role:	PI
ID:	2013-0479 (Formally 2005-0813CML)

Selected Publications

Peer-Reviewed Articles

Htut TW, Kekedjian J, Short N, Bazinet A, Alvarado Y, Bataller A, Issa G, Borthakur G, Maiti A, Yilmaz M, Jain N, Masarova L, Chien K, Senapati J, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Garcia-Manero G, Ravandi F. Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia. Haematologica, 2026. e-Pub 2026. PMID: 42389833.
Kadia TM, Bataller A, Bazinet A, Borthakur G, Daver N, Short NJ, DiNardo C, Jabbour E, Rausch CR, Issa GC, Pemmaraju N, Ohanian M, Maiti A, Montalban-Bravo G, Sasaki K, Bouligny IM, Yilmaz M, Haddad FG, Masarova L, Chien K, Alvarado Y, Jain N, Popat U, Shpall E, Loghavi S, Qiao W, Wang X, Garcia-Manero G, Ravandi F, Kantarjian HM. Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 101(7):1737-1747, 2026. e-Pub 2026. PMID: 42035228.
Jabbour E, Rausch CR, Goulart H, Jain N, Ravandi F, Maiti A, Alvarado Y, Burger J, Yilmaz M, Khouri I, Kebriaei P, Jorgensen J, Wang SA, Wang X, Mayor E, Garris RS, Short NJ, Kantarjian H. Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia. Blood Cancer J, 2026. e-Pub 2026. PMID: 42365008.
Nguyen D, Kantarjian HM, Bidikian A, Manuel CM, Qiao W, Ning J, DiNardo CD, Kadia TM, Daver N, Borthakur G, Jabbour E, Yilmaz M, Maiti A, Sasaki K, Montalban-Bravo G, Chien K, Hammond D, Pierce S, Andreeff M, Ravandi F, Short NJ, Garcia-Manero G, Issa GC. Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia. Clin Cancer Res, 2026. e-Pub 2026. PMID: 42329225.
Short NJ, Kantarjian HM, Daver NG, Azevedo RS, Karrar O, DiNardo CD, Kadia TM, Yilmaz M, Maroun MM, Hachem MCR, Borthakur G, Issa GC, Shpall EJ, Popat UR, Huang X, Qiao W, Nasr LF, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F. Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML. Blood Adv, 2026. e-Pub 2026. PMID: 42200455.
Bazinet A, Ferrajoli A, Jain N, Burger JA, Yilmaz M, Swaminathan M, Kantarjian HM, Keating M, Thompson PA, Wierda WG. NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy. Blood Adv 10(12):4113-4116, 2026. e-Pub 2026. PMID: 41879712.
Goulart H, Short NJ, Borthakur G, Jain N, DiNardo CD, Loghavi S, Khouri R, Hachem MCR, Ravandi F, Daver NG, Kadia TM, Yilmaz M, Issa GC, Bazinet A, Swaminathan M, Montalban-Bravo G, Haddad FG, Garris R, Kantarjian HM, Jabbour E. Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia. Blood Adv 10(9):3276-3280, 2026. e-Pub 2026. PMID: 41860396.
Haddad FG, Jabbour E, Sasaki K, Black S, Savoy JM, Alvarado Y, Borthakur G, Pemmaraju N, Yilmaz M, Delasalla S, Issa GC, Kantarjian H. Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis. Clin Lymphoma Myeloma Leuk, 2026. e-Pub 2026. PMID: 41876352.
Senapati J, Konopleva M, Issa GC, Jabbour E, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Short NJ, Yilmaz M, Deshmukh I, Alvarez J, Loghavi S, Tang G, Abbas HA, Andreeff M, Bhalla K, Midde NM, Said N, Noyalis A, Mires DE, Ning J, Xiao L, Ravandi F, Garcia-Manero G, Kantarjian HM, Daver NG. A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias. J Hematol Oncol 18(1):108, 2025. e-Pub 2025. PMID: 41310838.
DiNardo CD, Jen WY, Montalban-Bravo G, Wang X, Loghavi S, Lavu S, Short NJ, Chien K, Issa GC, Pemmaraju N, Yilmaz M, Andreeff M, Borthakur G, Kadia TM, Daver NG, Garcia-Manero G, Mill CP, Su X, Fiskus W, Bhalla KN. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. Blood Neoplasia 2(4):100145, 2025. e-Pub 2025. PMID: 40979071.
Azevedo RS, Braish J, Gener-Ricos G, Tang G, Sasaki K, Montalban-Bravo G, Jabbour E, Ohanian M, Yilmaz M, Haddad FG, Chien K, Ishizawa J, Short NJ, Maiti A, Swaminathan M, Kantarjian H, Borthakur G, Kadia TM. Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia. Leuk Lymphoma 67(1):1-5, 2025. e-Pub 2025. PMID: 41173347.
Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N. Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor. Haematologica 111(4):1246-1253, 2025. e-Pub 2025. PMID: 41035402.
Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39(10):2538-2541, 2025. e-Pub 2025. PMID: 40813623.
Urrutia S, Jen WY, Sasaki K, Wiernik PH, Kadia T, Daver N, DiNardo CD, Garcia-Manero G, Jabbour E, Short NJ, Issa G, Ravandi F, Yilmaz M. Mortality and relapse dynamics in AML after three years of complete remission. Leuk Lymphoma:1-6, 2025. e-Pub 2025. PMID: 40827386.
Arora, S, Jen, WY, Yilmaz, M, Deshmukh, I, Senapati, J, Loghavi, S, Issa, GC, Short, NJ, Kadia, TM, DiNardo, C, Borthakur, G, Jabbour, J, Pemmaraju, N, Andreeff, M, Takahashi, K, Bhalla, K, Popat, UR, Shpall, E, Oran, B, Abbas, HA, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations. Cancer 131(16), 2025. e-Pub 2025. PMID: 40782343.
Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
Kugler E, Dasdemir E, Bataller A, Wang B, DiNardo CD, Daver N, Yilmaz M, Short NJ, Borthakur G, Kadia TM, Sasaki K, Hammond D, Bazinet A, Irajizad E, Thakral B, Pierce S, Reville P, Ravandi F, Abbas HA. Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions. Leuk Lymphoma 66(7):1221-1233, 2025. e-Pub 2025. PMID: 40164144.
Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Montalban Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis. Clin Cancer Res 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol 43(24):JCO2500640, 2025. e-Pub 2025. PMID: 40513054.
Braish, JS, Montalban Bravo, G, Ravandi-Kashani, F, Short, NJ, Kadia, TM, Ohanian, M, Chien, KS, Masarova, L, Sasaki, K, Yilmaz, M, Logahvi, S, Daver, N, Borthakur, G, Jabbour, EJ, Schneider, H, Romero, LT, Kantarjian, HM, Garcia-Manero, G. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leukemia Research 153, 2025. e-Pub 2025. PMID: 40252309.
Ravandi-Kashani, F, Rangaraju, S, Kantarjian, HM, Garcia-Manero, G, Yilmaz, M, Baker, K, Hall, T, Grabenstein, J, Roy, P, Zamboni, BA, Zamboni, WC, Warlick, E, Kelly, MJ, Roth, D, Ghiaur, G. A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia. Blood Advances 9(9):2136-2143, 2025. e-Pub 2025. PMID: 40020161.
Goulart, H, Kantarjian, HM, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Pemmaraju, N, Alvarado, Y, Atluri, H, Yilmaz, M, Haddad, FG, Marx, K, Rausch, C, Loghavi, S, Jain, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia. Cancer 131(8), 2025. e-Pub 2025. PMID: 40193193.
DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
Bazinet, A, Bataller Torralba, A, Kadia, TM, Daver, N, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6), 2025. e-Pub 2025. PMID: 40097915.
Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, Ferrajoli A, Sasaki K, Alvarado Y, Pemmaraju N, Senapati J, Garris R, Ravandi F, Jabbour E. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1):e35662, 2025. e-Pub 2025. PMID: 39584789.
Herstein JE, Marx KR, Savoy JM, Jen WY, Yilmaz M, Short NJ, Issa GC, Ravandi F, Kadia TM, Daver NG, DiNardo CD. Case Report: FIA plus venetoclax in a patient on hemodialysis. Front Oncol 15:1740357, 2025. e-Pub 2025. PMID: 41626172.
Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2024. e-Pub 2024. PMID: 39665206.
Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, Ahmed S, Yilmaz M, Daver N, Ravandi F, DiNardo C, Short NJ, Kadia T, Al-Atrash G, Daher M, Costa DM, Popat U, Champlin R, Shpall E, Oran B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
Jen WY, Sasaki K, Loghavi S, Wang SA, Qiao W, Borthakur G, Ravandi F, Kadia TM, Issa GC, Short NJ, Yilmaz M, Daver NG, DiNardo CD. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol 204(6):2259-2263, 2024. e-Pub 2024. PMID: 38603594.
Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. e-Pub 2024. PMID: 38804782.
Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian H. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk 24(6):375-381, 2024. e-Pub 2024. PMID: 38431521.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol 42(13):1499-1508, 2024. e-Pub 2024. PMID: 38277619.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
Jen W, Sasaki K, Rausch CR, DiNardo CD, Kadia TM, Yilmaz M, Borthakur G, Alvarado Y, McCue D, McCue D, Kantarjian HM, Ravandi F. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. Leuk Lymphoma 65(3):378-382, 2023. e-Pub 2023. PMID: 38054837.
Ravandi F, Bashey A, Foran JM, Stock W, Mawad R, Short NJ, Yilmaz M, Kantarjian HM, Odenike O, Patel AA, Garcha R, Ainsworth WB, Clynes R, Kanodia J, Ding Y, Li H, Kye S, Mims AS. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv 7(21):6492-6505, 2023. e-Pub 2023. PMID: 37647601.
Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
Yilmaz M, Daver N. Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia. Lancet Haematol 10(8):e559-e561, 2023. e-Pub 2023. PMID: 37532412.
Short NJ, Ong F, Ravandi F, Nogueras Gonzalez GM, Kadia TM, Daver NG, DiNardo CD, Konopleva MY, Borthakur G, Oran B, Al-Atrash G, Mehta RS, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian HM, Shpall EJ, Popat UR. Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
Bazinet A, Kadia TM, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen JL, Patel KP, DiNardo CD, Daver NG, Alvarado Y, Haddad FG, Pierce SR, Nogueras Gonzalez GM, Maiti A, Sasaki K, Yilmaz M, Thompson PA, Wierda WG, Garcia-Manero G, Andreeff M, Jabbour EJ, Konopleva MY, Huang X, Kantarjian HM, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel K, Kanagal-Shamanna R, Champlin R, Khouri I, Dellasala S, Pierce SA, Kantarjian H. The Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line BCR::ABL1 Tyrosine Kinase Inhibitors. Am J Hematol 98(4):658-665, 2023. e-Pub 2023. PMID: 36683287.
Issa GC, Bidikian A, Venugopal S, Konopleva MY, DiNardo CD, Kadia TM, Borthakur G, Jabbour EJ, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SR, Takahashi K, Tang G, Loghavi S, Patel KP, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver NG. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2022. PMID: 36322818.
Abbas HA, Sun H, Pierce SR, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour EJ, Konopleva MY, Short NJ, DiNardo CD, Daver NG, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv 7(5):828-831, 2023. e-Pub 2022. PMID: 35405739.
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia. Am J Hematol 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 9(12):e878-e885, 2022. e-Pub 2022. PMID: 36279879.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97(11):E408-E411, 2022. e-Pub 2022. PMID: 36054774.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas H, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
Ong, F, Kadia, TM, Short, NJ, Yilmaz, M, Alvarado, Y, Sasaki, K, Pierce, S, Garcia-Manero, G, DiNardo, C, Borthakur, G, Konopleva, M, Daver, N, Kantarjian, HM, Ravandi-Kashani, F. AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clinical Lymphoma, Myeloma and Leukemia 22:S258, 2022. e-Pub 2022. PMID: 36163855.
Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. e-Pub 2022. PMID: 36163813.
Abuasab, T, Mohamed, SF, Biostatistics, HH, Biostatistics, XW, Sasaki, K, Yilmaz, M, Kadia, TM, DiNardo, C, Daver, N, Pemmaraju, N, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, Takahashi, K. AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD). Clinical Lymphoma, Myeloma and Leukemia 22:S243, 2022. e-Pub 2022. PMID: 36163827.
Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma:1-12. e-Pub 2022. PMID: 36089905.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol 97(3):322-328, 2022. e-Pub 2022. PMID: 34981560.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):1-4, 2022. e-Pub 2021. PMID: 34668451.
Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):1-5. e-Pub 2021. PMID: 34474640.
Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. e-Pub 2021. PMID: 34329576.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. e-Pub 2021. PMID: 34343352.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. e-Pub 2021. PMID: 34255353.
Tanaka T, Morita K, Wang F, Loghavi S, Furudate K, Sasaki Y, Little LD, Gumbs CE, Matthews J, Daver NG, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal A, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood. e-Pub 2021. PMID: 34115096.
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 14(1):94, 2021. e-Pub 2021. PMID: 34130720.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. e-Pub 2021. PMID: 34110383.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol:JCO2003736. e-Pub 2021. PMID: 34043428.
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. e-Pub 2021. PMID: 33793964.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. e-Pub 2021. PMID: 33891709.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. e-Pub 2021. PMID: 33740268.
Aitken MJL, Benton CB, Issa GC, Sasaki K, Yilmaz M, Short NJ. Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer. Acta Haematol:1-6. e-Pub 2021. PMID: 33735874.
Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SA. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol 192(6):1054-1063, 2021. e-Pub 2021. PMID: 33618432.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. e-Pub 2021. PMID: 33580980.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce S, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short N, Issa G, Ohanian M, Garcia-Manero G, Bhalla K, Patel K, Takahashi K, Andreeff M, Cortes J, Kantarjian H, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery(2):1-10, 2021. e-Pub 2021.
Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. e-Pub 2020. PMID: 33351107.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. e-Pub 2020. PMID: 33264443.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. e-Pub 2020. PMID: 33119202.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. e-Pub 2020. PMID: 32896301.
Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma:1-5. e-Pub 2020. PMID: 32955970.
Thakral B, Daver N, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury JD, Alotaibi AS, Konopleva M, Yilmaz M, Medeiros LJ. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma:1-4. e-Pub 2020. PMID: 32696696.
Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. e-Pub 2020. PMID: 32499238.
Yilmaz M, Kadia T, Ravandi F. Identifying effective drug combinations for patients with acute myeloid leukemia. Expert Rev Anticancer Ther:1-11. e-Pub 2020. PMID: 32552126.
Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2020. PMID: 32035785.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis. e-Pub 2020. PMID: 32236406.
Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2020. PMID: 31553487.
Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol 10:588876, 2020. e-Pub 2020. PMID: 33194747.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. e-Pub 2019. PMID: 31724006.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Yilmaz, M, Naqvi, K, Ravandi, F. Current and emerging treatments for acute promyelocytic leukemia. Expert Opinion on Orphan Drugs 7(11):453-461, 2019. e-Pub 2019.
Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer 125(18):3219-3224, 2019. e-Pub 2019. PMID: 31150121.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1-8, 2019. e-Pub 2019. PMID: 30632841.
Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer 125(13):2233-2241, 2019. e-Pub 2019. PMID: 30861111.
Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 125(7):1091-1100, 2019. e-Pub 2019. PMID: 30521114.
Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2018. PMID: 29178361.
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241-244, 2018. e-Pub 2018. PMID: 28919634.
Yilmaz M, Kantarjian H, Jabbour E. Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol 15(4):266-274, 2017. e-Pub 2017. PMID: 28591103.
Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2017. PMID: 27602508.
Pacheco JM, Yilmaz M, Rice L. How low is too low: Statin induced hemolysis. Am J Hematol 91(2):267, 2016. e-Pub 2016. PMID: 26147873.
Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894-904, 2015. e-Pub 2015. PMID: 26217876.
Mattiuzzi G, Yilmaz M, Kantarjian H, Borthakur G, Konopleva M, Jabbour E, Brown Y, Pierce S, Cortes J. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. J Infect Chemother 21(9):663-7, 2015. e-Pub 2015. PMID: 26141814.
Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk 13(6):693-9, 2013. e-Pub 2013. PMID: 24060289.
Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 48(9):1218-23, 2013. e-Pub 2013. PMID: 23503529.

Invited Articles

Yilmaz M, Kantarjian H, Jabbour E. ALL in Older Adults: Novel Treatment Modalities. Oncology Times 39(20):1, 11-16, 2017. e-Pub 2017.

Review Articles

Jen WY, Lachowiez CA, Marvin-Peek J, Altman JK, Yilmaz M, Garcia JS, Abaza Y, Short NJ, Zeidner JF, Daver NG, Wei AH, Issa GC, DiNardo CD. Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide. Blood Cancer J, 2025. e-Pub 2025. PMID: 41290614.
Bataller A, Short NJ, Daver N, Yilmaz M, Kantarjian H, Ravandi F. Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy. Curr Oncol Rep 27(9):1097-1105, 2025. e-Pub 2025. PMID: 40748523.
Kantarjian, H, Borthakur, G, Daver, N, DiNardo, CD, Issa, GC, Jabbour, EJ, Kadia, TM, Sasaki, K, Short, NJ, Yilmaz, M, Ravandi, F. Current status and research directions in acute myeloid leukemia. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39300079.
Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, Yilmaz M, Borthakur G, Ravandi F, Daver NG. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br J Haematol 205(1):30-47, 2024. e-Pub 2024. PMID: 38724457.
Narli Özdemir Z, Kiliçaslan NA, Yilmaz M, Eskazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol 117(1):3-15, 2023. e-Pub 2022. PMID: 36064839.
Haddad FG, Issa GC, Jabbour E, Yilmaz M. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia. Expert Opin Pharmacother 23(7):751-758, 2022. e-Pub 2022. PMID: 35412404.
Yilmaz M, Verstovsek S. Managing patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol 15(3):233-241, 2022. e-Pub 2022. PMID: 35316110.
Hein K, Short N, Jabbour E, Yilmaz M. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood Lymphat Cancer 12:7-16, 2022. e-Pub 2022. PMID: 35340663.
Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J 11(6):123, 2021. e-Pub 2021. PMID: 34193815.
Yilmaz M, Ravandi F. The potential role of Bi-specific antibodies in acute myeloid leukemia. Best Pract Res Clin Haematol 33(4):101218, 2020. e-Pub 2020. PMID: 33279174.
Yilmaz M, Daver N. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. Drugs 79(11):1177-1186, 2019. e-Pub 2019. PMID: 31222627.
Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol 16(3):216-223, 2018. e-Pub 2018. PMID: 29742077.
Yilmaz M, Jabbour E. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia. Semin Oncol 42(6):876-86, 2015. e-Pub 2015. PMID: 26615132.
Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol 6(5):253-61, 2015. e-Pub 2015. PMID: 26425338.
Yilmaz M, Abaza Y, Jabbour E. Selecting the best frontline treatment in chronic myeloid leukemia. Curr Hematol Malig Rep 10(2):145-57, 2015. e-Pub 2015. PMID: 25921387.

Abstracts

Yilmaz M, Kadia T, DiNardo C, Short N, Cooper C, Borthakur G, Pemmaraju N, Alvarado Y, Haddad F, Chien K, Jen W, Bazinet A, Loghavi S, Kornblau S, Andreeff M, Jabbour E, Ravandi F, Garcia-Manero G, Kantarjian H, Daver N. PHASE I/PHASE 2 STUDY OF QUIZARTINIB COMBINED WITH CLIA IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY FLT3-MUTATED AND WILD-TYPE ACUTE MYELOID LEUKEMIA. European Hematology Association (EHA), 2026. e-Pub 2026.
Yilmaz M, Muftuoglu M, DiNardo C, Kadia T, Konopleva M, Chan O, Borthakur G, Pemmaraju N, Short N, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Loghavi S, Sallman D, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, Daver N. TRIPLET THERAPY WITH QUIZARTINIB, DECITABINE, AND VENETOCLAX IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY FLT3-ITD ACUTE MYELOID LEUKEMIA. European Hematology Association (EHA), 2026. e-Pub 2026.
Yilmaz M, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva M, Chan O, Borthakur G, Pemmaraju N, Short NJ, Valero YA, Maiti A, Masarova L, Montalban-Bravo G, Loghavi S, Kornblau SM, Sallman DA, Jabbour E, Ravandi-Kashani F, Andreeff M, Daver NG. Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory FLT3-mutated AML. J Clin Oncol (ASCO Annual Meeting), 2026. e-Pub 2026.
Marvin-Peek J, Garcia JS, Borthakur G, Short NJ, Luskin MR, Lachowiez CA, Kadia TM, Daver NG, Issa GC, Traer EA, Swords RT, Jain AG, Yilmaz M, Wilson D, Boer L, Ravandi-Kashani F, Carraway HE, Garcia-Manero G, Kantarjian HM, DiNardo CD. A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML). J Clin Oncol (ASCO Annual Meeting), 2026. e-Pub 2026.
Swaminathan M, Jain N, Lovell A, Dinh A, Ferrajoli A, Burger J, Yilmaz M, Kadia T, Masarova L, Valero YA, Bose P, Ravandi F, Sasaki K, Qiao W, Li Z, Garg N, Keating M, Wierda W. Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Goulart H, Rausch C, Jabbour E, Maiti A, McCall D, Daver N, Short N, Pemmaraju N, Yilmaz M, Hammond D, Kornblau S, Issa G, Cuglievan B, Ravandi F, Kantarjian H. Multi arm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Azevedo RS, Short N, Bataller A, Daver N, Kadia T, DiNardo C, Bazinet A, Issa G, Jabbour E, Borthakur G, Senapati J, Jen W, Chien K, Kornblau S, Tippett D, Yilmaz M, Montalban-Bravo G, Kantarjian H, Garcia-Manero G, Ravandi F. Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Bouligny I, Chien K, Montalban-Bravo G, Bazinet A, Bataller A, Swaminathan M, Hammond D, Jen W, Kugler E, Jabbour E, Valero YA, Daver N, Kadia T, Andreeff M, Borthakur G, Jain N, Pemmaraju N, Ravandi F, Masarova L, Short N, Takahashi K, Yilmaz M, DiNardo C, Kanagal-Shamanna R, Mirabella B, Garcia-Manero G. A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes. Blood, 2025. e-Pub 2025.
Smallbone P, Loghavi S, Alatrash G, Dinc-Oran A, Takahashi K, Rondon G, Mazouzi K, Popat U, Champlin R, Daver N, Yilmaz M, Short N, Ramdial J, Aljawai Y, Patel K, Routbort M, Hammond D, Marin D, Shpall E, Oran B. Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Rausch C, Borthakur G, Haddad F, Chien K, Hammond D, Montalban-Bravo G, Pemmaraju N, Masarova L, Yilmaz M, Andreeff M, Jabbour E, Burger J, Jain N, Ravandi F, Kadia T. Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Issa G, Kantarjian H, Yilmaz M, Short N, Kadia T, Hajjar GE, DiNardo C, Alvarado Y, Jabbour E, Borthakur G, Pemmaraju N, Ravandi F, Andreeff M, Garcia-Manero G, Daver N. Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Bharathi V, Bouligny I, Almanza E, Bataller A, Bazinet A, Jen W, Khaire N, Sasaki K, Hammond D, DiNardo C, Borthakur G, Kadia T, Daver N, Issa G, Yilmaz M, Chien K, Montalban-Bravo G, Garcia-Manero G. Luspatercept response predictors in lower-risk myelodysplastic syndrome. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Arora S, Jen W, Bazinet A, Maiti A, Issa G, Kadia T, Borthakur G, Ravandi F, Valero YA, Yilmaz M, Ok CY, Fang H, Quesada A, Kanagal-Shamanna R, Jelloul F, Patel K, Medeiros L, Kantarjian H, Daver N, DiNardo C, Loghavi S. Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Burger JA, Kim E, Jayachandran G, Lopez W, Issa GC, Yilmaz M, Swaminathan M, Ishizawa J, Bazinet A, Valero YA, Jain N, Wierda WG, Ferrajoli A. A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Senapati J, Jabbour E, Jain N, Chien K, Yilmaz M, Haddad F, Montalban-Bravo G, Kugler E, Jen W, Khouri R, Ohanian M, Garris R, Zhao M, Garcia-Manero G, Short N, Kantarjian H. Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial. Blood (ASH Annual Meeting), 2025. e-Pub 2025.
Bazinet A, Ravandi F, Daver N, Short N, Ohanian M, Yilmaz M, Sasaki K, Jabbour E, Chien K, DiNardo C, Haddad F, Hammond D, Ishizawa J, Jain N, Maiti A, Masarova L, Wierda W, Garcia-Manero G, Kantarjian H, Kadia T. A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia. Blood, 2025. e-Pub 2025.
Yilmaz M, Muftuoglu M, Short N, Loghavi S, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Alvarado Y, Maiti A, Konopleva M, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Patel K, Tang G, Kornblau S, Jabbour E, Takahashi K, Ravandi-Kashani F, Andreeff M, Kantarjian H, Daver N. PHASE I/II STUDY OF DECITABINE, VENETOCLAX, AND QUIZARTINIB TRIPLET COMBINATION IN FLT3-ITD MUTATED AML. European Hematology Association (EHA), 2025. e-Pub 2025.
Arora S, Kantarjian HM, Daver NG, Loghavi S, Kadia TM, Dinardo CD, Yilmaz M, Issa GC, Pierce S, Gaw KM, Ravandi-Kashani F, Short NJ. Cytomolecular mechanisms of relapse after frontline FLT3 inhibitor (FLT3i)-based therapy in FLT3-mutated (mut) acute myeloid leukemia (AML). J Clin Oncol (ASCO Annual Meeting), 2025. e-Pub 2025.
Azevedo RS, Wang SA, Daver NG, Pemmaraju N, Kadia TM, Issa GC, Yilmaz M, Borthakur G, Jen WY, Short NJ, Ravandi-Kashani F, Wang W, Fang H, Xu J, Patel K, Tang G, Medeiros L, Kantarjian HM, Dinardo CD, Loghavi S. CD123 expression and its correlation with mutation profile in acute myeloid leukemia. J Clin Oncol (ASCO Annual Meeting), 2025. e-Pub 2025.
Farhat A, Kantarjian HM, Sasaki K, Short NJ, Cuglievan B, Loghavi S, Patel KP, Bataller A, Yilmaz M, Montalban-Bravo G, Hammond D, Pemmaraju N, Daver N, Ravandi F, Jabbour E, Kadia TM, Borthakur G, Garcia-Manero G, DiNardo CD, Issa GC. Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Swaminathan M, Thompson PA, Burger JA, Yilmaz M, Jain N, Kadia TM, Masarova L, Valero YA, Bose P, Ferrajoli A, Issa GC, Kornblau SM, Ravandi F, Sasaki K, Borthakur G, Chien KS, DiNardo CD, Hammond D, Jabbour E, Montalban-Bravo G, Pemmaraju N, Short NJ, Takahashi K, Tambaro FP, Qiao W, Garg N, Keating MJ, Wierda WG. Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Croden J, Marvin-Peek J, Konopleva M, Borthakur G, Daver N, Abbas HA, Takahashi K, Sasaki K, Garcia-Manero G, Jain N, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Valero YA, Kornblau SM, Ravandi F, Kantarjian H, Kadia TM, DiNardo CD. Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, McCall D, Pike A, Tan S, Kammerer B, Marshal A, Yilmaz M, Kadia TM, Pemmaraju N, Ohanian M, Abbas HA, Maiti A, Bazinet A, Jabbour E, Sasaki K, Borthakur G, Montalban-Bravo G, Jain N, Valero YA, Ravandi F, Garcia-Manero G, Andreeff M, Kantarjian HM. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Yilmaz M, Muftuoglu M, Short NJ, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Pemmaraju N, Valero YA, Maiti A, Konopleva M, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Patel KP, Tang G, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Takahashi K, Andreeff M, Ravandi F, Kantarjian HM, Daver N. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Arora S, Senapati J, Loghavi S, Reville PK, Wang B, Kadia TM, DiNardo CD, Pemmaraju N, Yilmaz M, Jabbour JE, Short NJ, Montalban-Bravo G, Maiti A, Tang G, Sasaki K, Borthakur G, Alvarez J, Pierce S, Nogueras González GM, Ning J, Issa GC, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA, Daver N. Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Bouligny IM, Kantarjian HM, Yilmaz M, Daver N, Borthakur G, DiNardo CD, Montalban-Bravo G, Short NJ, Valero YA, Jain N, Pemmaraju N, Hammond D, Chien KS, Takahashi K, Issa GC, Abbas HA, Jabbour E, Garcia-Manero G, Ravandi F, Kadia TM. Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Nguyen D, Ravandi F, Wang SA, Jorgensen JL, WANG W, Loghavi S, Lee J, Bachireddy P, DiNardo CD, Chien KS, Montalban-Bravo G, Issa GC, Maiti A, Valero YA, Daver N, Jabbour E, Kadia TM, Pemmaraju N, Yilmaz M, Nguyen DT, Popat U, Shpall EJ, Garcia-Manero G, Kantarjian H, Short NJ. Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Marvin-Peek J, Atluri H, Short NJ, Maiti A, Takahashi K, Loghavi S, Lachowiez CA, Valero YA, Montalban-Bravo G, Sasaki K, Haddad FG, Issa GC, Masarova L, Abbas HA, Andreeff M, Borthakur G, Mullin J, Tippett GD, Chien KS, Hammond D, Ishizawa J, Jain N, Reville PK, Swaminathan M, Yilmaz M, Daver N, Kadia TM, Ravandi F, Garcia-Manero G, Kantarjian HM, DiNardo CD. Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Bazinet A, Garcia-Manero G, Bataller A, Valero YA, Yilmaz M, Jabbour E, Montalban-Bravo G, Pemmaraju N, Issa GC, Short NJ, Kadia TM, Jain N, Masarova L, Daver N, Hammond D, Borthakur G, Maiti A, Takahashi K, Chien KS, Kornblau SM, Abbas HA, Ohanian M, Senapati J, DiNardo CD, Kantarjian HM, Ravandi F. Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Arora S, Yilmaz M, Jen W, Short NJ, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Deshmukh I, Issa GC, Jabbour JE, Pemmaraju N, Andreeff M, Takahashi K, Bhalla KN, Abbas HA, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver N. Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Hammond D, Sasaki K, Takahashi K, Shpall EJ, Popat U, Oran B, Al-Atrash G, Patel KK, Westin JR, Neelapu SS, Alvarado-Valero Y, Chien KS, Daver N, Montalban-Bravo G, Maiti A, Yilmaz M, Jabbour E, Pemmaraju N, Swaminathan M, Ishizawa J, Jain N, Ferrajoli A, Ravandi F, Kornblau SM, Borthakur G, Garcia-Manero G, Kantarjian HM, Reville PK, Abbas HA. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Marvin-Peek J, Jen W, Short NJ, Issa GC, Yilmaz M, Montalban-Bravo G, Bazinet A, Sasaki K, Maiti A, Borthakur G, Hammond D, Chien KS, Abbas HA, Pemmaraju N, Garcia-Manero G, Jabbour E, Ravandi F, Kadia TM, Daver N, DiNardo CD. Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Bouligny IM, Kantarjian HM, Yilmaz M, Daver N, Borthakur G, DiNardo CD, Montalban-Bravo G, Short NJ, Valero YA, Jabbour E, Jain N, Pemmaraju N, Hammond D, Chien KS, Takahashi K, Issa GC, Abbas HA, Garcia-Manero G, Ravandi F, Kadia TM. A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Senapati J, DiNardo CD, Kadia TM, Khaire NS, Haddad FG, Loghavi S, Tang G, Deshmukh I, Jabbour JE, Issa GC, Short NJ, Yilmaz M, Hammond D, Borthakur G, Abbas HA, Bazinet A, Pierce S, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian HM, Daver N. Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Short NJ, Loghavi S, Yilmaz M, Karrar O, Jabbour JE, DiNardo CD, Kadia TM, Borthakur G, Issa GC, Abbas HA, Konopleva M, Ravandi F, Kantarjian HM, Daver N. Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Goulart H, Kantarjian HM, Daver N, Yilmaz M, Garcia-Manero G, Chien KS, Burger JA, Pemmaraju N, DiNardo CD, Short NJ, Montalban-Bravo G, Maiti A, Hammond D, Issa GC, Jabbour E, Ravandi F, Kadia TM. A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Senapati J, Kantarjian HM, Ayoub E, Jain A, Kadia TM, DiNardo CD, Daver N, Haddad FG, Pemmaraju N, Short NJ, Ohanian M, Yilmaz M, Patel KP, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Borthakur G. Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Bazinet A, Daver N, Ravandi F, Short NJ, Yilmaz M, Ohanian M, Ishizawa J, Maiti A, DiNardo CD, Masarova L, Wierda WG, Chien KS, Jabbour E, Hammond D, Haddad FG, Sasaki K, Bataller A, Bull-Linderman D, Borthakur G, Garcia-Manero G, Kantarjian HM, Kadia TM. Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Nguyen D, Kantarjian H, Short NJ, Jain N, Haddad FG, Yilmaz M, Ferrajoli A, Kadia TM, Valero YA, Maiti A, Zoghbi M, Senapati J, Garris R, Zhao M, Konopleva M, Ravandi F, Jabbour E. Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Jain N, Ferrajoli A, Swaminathan M, Reville PK, Burger JA, Bharathi V, Atluri H, Cherng HJ, Bataller A, Jabbour E, Kadia TM, Borthakur G, Takahashi K, Chien KS, Yilmaz M, Pemmaraju N, Daver N, Haddad FG, Valero YA, Ishizawa J, Montalban-Bravo G, Garg N, Hwang H, Qiao W, Garcia C, Evangelio A, Ayala A, Sampath D, Gandhi V, Keating MJ, Kantarjian HM, Wierda WG. Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Braish J, Montalban-Bravo G, Ravandi F, Short NJ, Kadia TM, Ohanian M, Chien KS, Masarova L, Sasaki K, Yilmaz M, Daver N, Borthakur G, Kantarjian HM, Garcia-Manero G. Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Marvin-Peek J, DiNardo CD, Jen W, Short NJ, Valero YA, Borthakur G, Daver N, Kugler E, Bazinet A, Abbas HA, Yilmaz M, Garcia-Manero G, Kantarjian HM, Kadia TM. Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
DiNardo CD, Chien KS, Mullin J, Hammond D, Ramdial J, Kadia TM, Haddad FG, Yilmaz M, Sasaki K, Issa GC, Takahashi K, Shpall EJ, Ravandi F, Daver N, Kantarjian H. Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Burger JA, Kim E, Jayachandran G, Lopez W, Issa GC, Yilmaz M, Swaminathan M, Ishizawa J, Bazinet A, Valero YA, Jain N, Wierda WG, Ferrajoli A. A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Short NJ, Ravandi F, Daver N, DiNardo CD, Borthakur G, Kadia TM, Yilmaz M, Issa GC, Abramova R, Garza AI, Kantarjian HM, Abbas HA. A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress. Blood (ASH Annual Meeting), 2024. e-Pub 2024.
Jen WY, Takahashi K, Loghavi S, Kadia TM, Daver NG, Xiao L, Short NJ, Borthakur G, Issa GC, Pemmaraju N, Reville PK, Bravo GM, Yilmaz M, Garcia-Manero G, Ravandi-Kashani F, Konopleva M, Mullin JK, Pierce S, Kantarjian HM, Dinardo CD. FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML. J Clin Oncol (ASCO Annual Meeting), 2024. e-Pub 2024.
Kugler E, Dasdemir E, Wang B, Bataller A, Dinardo CD, Daver NG, Yilmaz M, Short NJ, Kadia TM, Sasaki K, Bazinet A, Pierce S, Reville PK, Ravandi-Kashani F, Abbas H. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions. J Clin Oncol (ASCO Annual Meeting), 2024. e-Pub 2024.
Ali A, Pierce E, Song J, Koutroumpakis E, Palaskas N, Deswal A, Daver NG, Kadia TM, Jain N, Yilmaz M, Borthakur G, Hammond D, Iliescu C, Pemmaraju N. Pilot study on the utilization of a non-invasive µCor device for monitoring fluid status and cardiac biomarkers during treatment for patients with hematologic malignancies. J Clin Oncol (ASCO Annual Meeting 2024), 2024. e-Pub 2024.
Nguyen D, Kantarjian HM, Short NJ, Jain N, Haddad FG, Yilmaz M, Ferrajoli A, Kadia TM, Valero YA, Maiti A, Nasnas C, Nasr L, Garris R, Konopleva MY, Ravandi F, Jabbour E. Updated Results from a Phase II Study of Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Valero YA, Montalban-Bravo G, Maiti A, Abbas HA, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Gener-Ricos G, Borthakur G, Sasaki K, Tang G, Montalban-Bravo G, Jabbour E, Ohanian M, Yilmaz M, Haddad FG, Chien KS, Ishizawa J, Short NJ, Maiti A, Swaminathan M, Garcia-Manero G, Daver N, DiNardo CD, Ravandi F, Kadia TM. Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results Georgina Gener-Ricos, Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban-Bravo, Elias Jabbour, Maro Ohanian, Musa Yilmaz, Fadi G. Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia-Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Urrutia S, Chien KS, Li Z, Borthakur G, Valero YA, Kadia TM, Kornblau SM, Daver N, Ravandi F, Bose P, Yilmaz M, Ohanian M, Kanagal-Shamanna R, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero G. Update of a Phase II Trial of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Under the International Working Group 2023 Criteria. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Briski R, Short NJ, Daver N, Kadia TM, DiNardo CD, Yilmaz M, Valero YA, Vaughan K, Pierce S, Montalbano K, Mullin J, Kantarjian HM, Garcia-Manero G, Ravandi F. A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Bazinet A, Kantarjian HM, Ravandi F, Short NJ, Daver N, Ohanian M, Yilmaz M, Chien KS, Maiti A, DiNardo CD, Ishizawa J, Masarova L, Bull-Linderman D, Borthakur G, Jabbour E, Garcia-Manero G, Kadia TM. Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Masarova L, Kantarjian HM, Pemmaraju N, Abbas HA, Bose P, Swaminathan M, Pierce S, Sasaki K, Yilmaz M, Short NJ, Daver N, Borthakur G, Garcia-Manero G, Ohanian M, Bhalla KN, DiNardo CD, Kadia TM. Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs). Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Arani N, Almanza E, Bataller A, DiNardo CD, Ravandi F, Daver N, Pemmaraju N, Yilmaz M, Maiti A, Reville PK, Loghavi S, Abbas HA, Garcia-Manero G, Short NJ, Kantarjian HM, Kadia TM. Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Jen W, Jabbour E, Haddad FG, Nasr L, Short NJ, Zoghbi M, Nasnas C, Issa GC, Yilmaz M, Daver N, Pemmaraju N, Masarova L, Ravandi F, Jain N, Deen W, Loiselle C, Waller L, Banks G, Garris R, Kantarjian HM. A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Bazinet A, Kantarjian HM, Borthakur G, Yilmaz M, Bose P, Jabbour E, Valero YA, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Daver N, Issa GC, Jain N, Hammond DE, Bull-Linderman D, DiNardo CD, Burger JA, Ferrajoli A, Montalban-Bravo G, Sasaki K, Garcia-Manero G, Ravandi F, Kadia TM. Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Swaminathan M, Takahashi K, Estrov Z, Konopleva MY, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Valero YA, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Nguyen D, Ravandi F, Wang SA, Jorgensen JL, Wang W, Chien KS, Montalban-Bravo G, Issa GC, Maiti A, Valero YA, Daver N, DiNardo CD, Jabbour E, Kadia TM, Pemmaraju N, Yilmaz M, Lee J, Bachireddy P, Popat UR, Garcia-Manero G, Kantarjian HM, Short NJ. A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Bazinet A, Kantarjian HM, Ravandi F, Short NJ, Daver N, Ohanian M, Yilmaz M, Chien KS, Maiti A, DiNardo CD, Ishizawa J, Masarova L, Bull-Linderman D, Borthakur G, Jabbour E, Garcia-Manero G, Kadia TM. Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Bataller A, Kantarjian HM, Kadia TM, Daver N, DiNardo CD, Borthakur G, Short NJ, Yilmaz M, Issa GC, Valero YA, Montalban-Bravo G, Maiti A, Abbas HA, Jabbour E, Wierda WG, Garcia-Manero G, Ravandi F. Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Bazinet A, Garcia-Manero G, Short NJ, Valero YA, Abuasab T, Islam MR, Montalbano K, Issa GC, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau SM, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia TM, Daver N, Konopleva MY, Kantarjian HM, Ravandi F. A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Issa GC, Cuglievan B, DiNardo CD, Short NJ, McCall D, Gibson A, Nunez C, Garcia MB, Roth M, Bidikian A, Pike A, Tan S, Kammerer B, Yilmaz M, Kadia TM, Pemmaraju N, Ohanian M, Daver N, Jabbour E, Borthakur G, Ravandi F, Garcia-Manero G, Andreeff M, Kantarjian HM. Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE). Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Yilmaz M, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, Pemmaraju N, Short NJ, Valero YA, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Loghavi S, Patel KP, Tang G, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, Daver N. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML. Blood (ASH Annual Meeting), 2023. e-Pub 2023.
Haddad F, Jabbour E, Nasr L, Short N, Macaron W, Nasnas C, Zoghbi M, Issa G, Yilmaz M, Daver N, Pemmaraju N, Masarova L, Ravandi F, Jain N, Deen W, Loiselle C, Waller L, Banks G, Garris R, Kantarjian H. A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. HemaSphere (EHA 2023), 2023. e-Pub 2023.
Short N, Jabbour E, Jain N, Haddad F, Yilmaz M, Nasr L, Ferrajoli A, Kadia T, Alvarado Y, Maiti A, Macaron W, Zoghbi M, Nasnas C, Garris R, Zhao M, Konopleva M, Ravandi F, Kantarjian H. HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY. HemaSphere (EHA 2023), 2023. e-Pub 2023.
Bidikian A, Haddad F, Sasaki K, Issa G, Kadia T, Jain N, Alvarado Y, Short N, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES. HemaSphere (EHA 2023), 2023. e-Pub 2023.
Nguyen D, Kantarjian H, Bidikian A, Dinardo C, Kadia T, Daver N, Borthakur G, Jabbour E, Yilmaz M, Short N, Maiti A, Sasaki K, Montalban-Bravo G, Hammond D, Pierce S, Andreeff M, Garcia-Manero G, Ravandi F, Issa G. OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND. HemaSphere (EHA 2023), 2023. e-Pub 2023.
Bazinet A, Arani N, Chien K, Hammond D, Kadia T, Borthakur G, Alvarado Y, Sasaki K, Dinardo C, Pemmaraju N, Masarova L, Short N, Yilmaz M, Daver N, Jabbour E, Ravandi F, Kanagal-Shamanna R, Pierce S, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS. HemaSphere (EHA 2023), 2023. e-Pub 2023.
Short N, Macaron W, Dinardo C, Daver N, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa G, Sasaki K, Burger J, Maiti A, Alvarado Y, Thankachan J, Abramova R, Nasr L, Nasnas C, Zoghbi M, Kadia T, Konopleva M, Kantarjian H, Ravandi F. AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY. HemaSphere (EHA 2023), 2023. e-Pub 2023.
Short NJ, Jabbour E, Jain N, Haddad F, Macaron W, Yilmaz M, Ferrajoli A, Kadia TM, Valero YA, Maiti A, Nasr LF, Zoghbi M, Nasnas CC, Garris R, Zhao M, Konopleva M, Ravandi F, Kantarjian HM. A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL). J Clinic Oncol (ASCO Annual Meeting), 2023. e-Pub 2023.
Nguyen H, Sasaki K, Ravandi F, Luthra R, Patel KP, Loghavi S, Jelloul FZ, Routbort M, Kalia A, Montalban-Bravo G, Chien KS, Hu P, Yilmaz M, Bueso-Ramos CE, Medeiros L, Garcia-Manero G, Kanagal-Shamanna R. Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Muftuoglu M, Yilmaz M, Basyal M, Li L, Seki T, Lesegretain A, Daver N, Andreeff M. Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Yeh J, Saliba RM, Wang C, Fang Z, Figgins B, Ahmed S, Yilmaz M, Daver N, Mehta RS, Alatrash G, Marin D, Popat UR, Champlin RE, Shpall EJ, Oran B. Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Haddad F, Sasaki K, Issa GC, Kim K, Skinner J, Dellasala SE, Alvarado Y, Ferrajoli A, Kadia TM, Yilmaz M, Pemmaraju N, Garcia-Manero G, Pierce SA, Jabbour E, Kantarjian H. More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Jabbour E, Sasaki K, Issa GC, Haddad F, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Pemmaraju N, Dellasala SE, Pierce SA, Cortes JE, Kantarjian H. Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Nguyen D, Jabbour E, Short N, Issa GC, Yilmaz M, Daver N, Pemmaraju N, Chien KS, Masarova L, Ravandi F, Jain N, Deen W, Zhao M, Loiselle C, Waller L, Banks G, Garris R, Kantarjian H. A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Desikan SP, Daver N, Loghavi S, Kadia TM, Short N, DiNardo CD, Borthakur G, Pierce SA, Patel KP, Abbas HA, Maiti A, Garcia-Manero G, Ravandi F, Kantarjian H, Yilmaz M. Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Ong F, Short N, Daver N, Kadia TM, DiNardo CD, Yilmaz M, Alvarado Y, Vaughan K, Pierce SA, Kantarjian H, Garcia-Manero G, Ravandi F. A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Desikan SP, Kantarjian H, Jabbour E, Chien KS, Montalban-Bravo G, Alvarado Y, Borthakur G, Issa GC, Daver N, Pemmaraju N, Yilmaz M, Hammond D, Maiti A, DiNardo CD, Ravandi F, Garcia-Manero G, Kadia TM. Cellular Immunotherapies| November 15, 2022 Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Abuasab T, Verstovsek S, Borthakur G, Kanagal-Shamanna R, Patel K, Takahashi K, Masarova L, Bose P, Villarreal J, Pierce SA, Montalban-Bravo G, Garcia-Manero G, Short N, DiNardo CD, Daver N, Ravandi F, Kantarjian H, Yilmaz M. The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Macaron W, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Daver N, Wang SA, Jorgensen JL, Patel K, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall EJ, Popat UR, Alatrash G, Pierce SA, Kantarjian H, Short N. Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Haddad F, Medawar G, Kanagal-Shamanna R, Alvarez H, Loghavi S, Daver N, Pierce SA, Jabbour E, Kadia TM, Short N, DiNardo CD, Borthakur G, Abbas HA, Pemmaraju N, Garcia-Manero G, Ravandi F, Kantarjian H, Yilmaz M. Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short N, Issa GC, Yilmaz M, Pierce SA, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia TM, Konopleva M, DiNardo CD, Ravandi F. Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Maiti A, DiNardo CD, Ohanian M, Pemmaraju N, Daver N, Borthakur G, Ravandi F, Issa GC, Garcia-Manero G, Jain N, Kadia TM, Masarova L, Wierda WG, Yilmaz M, Alvarado Y, Jabbour E, Short N, Takahashi K, Loghavi S, Patel KP, Montalbano K, Pierce SA, Bivins CA, Mehta RS, Alatrash G, Popat UR, Kebriaei P, Oran B, Shpall EJ, Champlin RE, Kantarjian H, Konopleva M. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. Blood, 2022. e-Pub 2022.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Konopleva M, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Alvarado Y, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Reville PK, Kantarjian H, Borthakur G, Yilmaz M, Daver N, Short N, DiNardo CD, Kornblau SM, Pemmaraju N, Jain N, Alvarado Y, Bose P, Jabbour E, Chien KS, Abbas HA, Masarova L, Wang SA, S Tidwell RS, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Daver N, Senapati J, Maiti A, Loghavi S, Kadia TM, DiNardo CD, Pemmaraju N, Jabbour E, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Pierce SA, Nogueras González GM, Ning J, Issa GC, Andreeff M, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Nasnas P, Jabbour E, Short N, Sasaki K, Ravandi F, Jain N, Daver N, Pemmaraju N, Yilmaz M, Kadia TM, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Wierda WG, Kwari M, Loiselle C, Milton A, Rivera J, Banks G, Kantarjian H. Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Short N, Jabbour E, Ravandi F, Yilmaz M, Kadia TM, Thompson PA, Huang X, Konopleva M, Ferrajoli A, Jain N, Sasaki K, Macaron W, Alvarado Y, Borthakur G, DiNardo CD, Ohanian M, Kornblau SM, Zhao M, Kwari M, Thankachan J, Loiselle C, Delumpa R, Garris R, Kantarjian H. The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Bazinet A, Kantarjian H, Arani N, Popat UR, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short N, Issa GC, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi AM, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia TM. Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien KS, Pemmaraju N, Takahashi K, Short N, Daver N, Issa GC, Jain N, Linderman DB, DiNardo CD, Burger JA, Ferrajoli A, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia TM. A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Desikan SP, Konopleva M, Takahashi K, Lachowiez CA, Loghavi S, Xiao L, Kadia TM, Daver N, Short N, Sasaki K, Borthakur G, Issa GC, Maiti A, Chien KS, Alvarado Y, Montalban-Bravo G, Masarova L, Yilmaz M, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian H, DiNardo CD. Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Short N, DiNardo CD, Daver N, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Sasaki K, Thompson PA, Burger JA, Maiti A, Alvarado Y, Kwari M, Delumpa R, Thankachan J, Mayor E, Loiselle C, Milton A, Banks G, Kadia TM, Konopleva M, Kantarjian H, Ravandi F. Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia. Blood (ASH Annual Meeting, 2022. e-Pub 2022.
Abuasab T, Garcia-Manero G, Short N, Alvarado Y, Issa GC, Islam R, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau SM, Jabbour E, Pemmaraju N, Montalban-Bravo G, Pierce SA, DiNardo CD, Kadia TM, Daver N, Konopleva M, Kantarjian H, Ravandi F. Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy. Blood (ASH Annual Meeting), 2022. e-Pub 2022.
Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo C, Kadia T, Borthakur G, Pemmaraju N, Short N, Alvarado Y, Maiti A, Masarova L, Bravo GM, Loghavi S, Patel K, Kornblau S, Jabbour E, Garcia-Manero G, Andreeff M, Daver N. QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY. European Hematology Association (EHA), 2022. e-Pub 2022.
Yilmaz M, Muftuoglu M, Kantarjian HM, Dinardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Valero YA, Maiti A, Masarova L, Bravo GM, Loghavi S, Kornblau SM, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, Daver NG. Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial. J Clin Oncol (ASCO Annual Meeting), 2022. e-Pub 2022.
Yilmaz M, Kantarjian H, Short NJ, Konopleva M, Kadia TM, DiNardo CD, Borthakur G, Pemmaraju N, Maiti A, Jabbour EJ, Issa GC, Jain N, Takahashi K, Sasaki K, Ohanian M, Tang G, Loghavi S, Patel K, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. Blood (ASH) 138(Suppl 1), 2021. e-Pub 2021.
Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike AM, Loghavi S, Patel K, Tang G, Matthews JA, Kornblau SM, Jabbour EJ, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) – RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood (ASH) 138(Suppl 1), 2021. e-Pub 2021.
Yilmaz M, Kantarjian H, Muftuoglu M, Dinardo C, Kadia T, Konopleva M, Borthakur G, Pemmaraju N, Short N, Alvarado Y, Maiti A, Montalban-Bravo G, Jurisprudencia C, Pike A, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS HIGHLY ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA. European Hematology Association (EHA), 2021. e-Pub 2021.
Yilmaz M, Ravandi F, Loghavi S, Wang S, Borthakur G, Dinardo C, Kadia T, Kanagal-Shammanna R, Pemmaraju N, Oran B, Popat U, Pierce S, Jabbour E, Short N, Issa G, Ohanian M, Garcia-Manero G, Andreeff M, Patel K, Konopleva M, Kantarjian H, Daver N. TRIPLE COMBINATION OF HMA, VENETOCLAX, AND FLT3 INHIBITOR PRODUCES HIGHER FLT3 PCR CLEARANCE, FLOW MRD NEGATIVITY, AND IMPROVED MEDIAN OS COMPARED WITH DOUBLETS OF HMA WITH FLT3 INHIBITOR. European Hematology Association (EHA), 2021. e-Pub 2021.
Yilmaz M, Ravandi F, Borthakur G, Kadia T, Dinardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat U, Pierce S, Jabbour E, Short N, Issa G, Pemmaraju N, Konopleva M, Patel K, Kantarjian H, Daver N. FLT3 INHIBITOR BASED INDUCTION AND ALLOGENEIC STEM CELL TRANSPLANT IN CR1 IMPROVE OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED AML VERY LOW FLT3 ALLELIC BURDEN. European Hematology Association (EHA), 2021. e-Pub 2021.
Rivera D, Kantarjian HM, Kadia TM, Daver NG, Dinardo CD, Short NJ, Yilmaz M, Jabbour E, Garcia-Manero G, Konopleva M, Borthakur G, Ravandi F. Characteristics and outcomes of patients diagnosed with DNMT3A mutated acute myeloblastic leukemia. Blood 137(Suppl 1), 2021. e-Pub 2021.
Yilmaz M, Kantarjian H, Muftuoglu M, Kadia T, Konopleva M, Borthakur G, DiNardo CD, Pemmaraju N, Short N, Alvarado Y, Montalban-Bravo G, Jurisprudencia C, Pike A, Ohanian M, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. Blood 136(Supplement 1):19-20, 2020. e-Pub 2020.
Yilmaz M, Alfayez M, Kadia T, DiNardo C, Borthakur G, Loghavi S, Konopleva M, Kanagal-Shamanna R, Patel K, Jabbour E, Garcia-Manero G, Pemmaraju N, Pierce S, Issa G, Short N, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi A, Andreeff M, Cortes J, Kantarjian H, Ravandi F, Daver N. Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3-Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies. Blood 136(Supplement 1):22-24, 2020. e-Pub 2020.
Jain N, Maiti A, Ravandi F, Konopleva M, Alvarado Y, Kadia T, Short N, Borthakur G, Naqvi K, Pemmaraju N, Dinardo C, Daver N, Yilmaz M, Patel K, Linderman D, Garris R, Jabbour E, Cortes J, Kantarjian H. Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP). J Clin Oncol (ASCO Annual Meeting) 136(Suppl 1), 2020. e-Pub 2020.
Kadia T, Garcia-Manero G, Yilmaz M, Dinardo C, Konopleva M, Montalban-Bravo G, Borthakur G, Jabbour E, Jain N, Andreeff M, Short N, Issa G, Ohanian M, Bose P, Daver N, Wang S, Tidwell R, Estrov Z, Ravandi F, Kantarjian H. Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol (ASCO Annual Meeting) 136(Suppl 1), 2020. e-Pub 2020.
Brümmendorf T, Cortes J, Goh Y, Yilmaz M, Klisovic R, Purcell S, Viqueira A, Leip E, Gambacorti-Passerini C. Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase I/II study. J Clin Oncol (ASCO Annual Meeting) 136(Suppl 1), 2020. e-Pub 2020.
Maiti A, DiNardo C, Rausch C, Cortes J, Pemmaraju N, Daver N, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short N, Alvarado Y, Benton C, Kadia T, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa G, Jabbour E, Masarova L, Rytting M, Thompson P, Wang S, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero J, Zhang Q, Cavazos A, Ma H, Bivins C, Wade A, Adewale S, Tse S, Thomas R, Vaughan K, Pierce S, Ning J, Qiao W, Welch J, Kantarjian H, Konopleva M. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Maiti A, Rausch C, Cortes J, Pemmaraju N, Daver N, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short N, Alvarado Y, Benton C, Kadia T, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa G, Jabbour E, Masarova L, Rytting M, Thompson P, Wang S, Konoplev S, Chen Z, Goswami M, MaduikeR, Guerrero J, Zhang Q, Cavazos A, Ma H, Bivins C, Wade A, Adewale S, Tse S, Thomas R, Vaughan K, Pierce S, Ning J, Qiao W, Welch J, Patel K, Kantarjian H, Konopleva M, DiNardo C. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Kantarjian H, Kadia T, Garcia-Manero G, Jabbour E, Borthakur G, Naqvi K, Short N, Alvarado Y, Yilmaz M, Daver N, McCue D, Pierce S, Cortes J, Shoukier M, Ravandi F. Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Aboudalle I, Konopleva M, Kadia T, Naqvi K, Vaughan K, Kurt M, Cavazos A, Pierce S, Takahashi K, Masarova L, Yilmaz M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Cortes J, Kantarjian H, DiNardo C. A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Jain N, Keating M, Thompson P, Burger J, Ferrajoli A, Estrov Z, Borthakur G, Takahashi K, Bose P, Fowler N, Kadia T, Daver N, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Wang S, Garg N, Wang X, Sondermann N, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Maiti A, Rausch C, Cortes J, Pemmaraju N, Daver N, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short N, Alvarado Y, Benton C, Kadia T, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa G, Jabbour E, Masarova L, Rytting M, Thompson P, Wang S, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero J, Zhang Q, Cavazos A, Ma H, Bivins C, Wade A, Adewale S, Tse S, Thomas R, Vaughan K, Pierce S, Ning J, Qiao W, Welch J, Kantarjian H, Konopleva M, DiNardo C. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Samra B, Kantarjian H, Sasaki K, Short N, Khouri R, Khoury J, Champlin R, Kebriaei P, Cortes J, Jorgensen J, Wang S, Garcia-Manero G, Kadia T, Borthakur G, Verstovsek S, Daver N, Montalban-Bravo G, Jain N, Konopleva M, Yilmaz M, Naqvi K, O'Brien S, Ravandi F, Jabbour E. Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Kadia T, Ma H, Zeng K, Nishimoto M, Lyu M, Huang M, Yilmaz M, DiNardo C, Issa G, Parmar S, Iyer S, Hari P, Daver N, Jabbour E, Borthakur G, Verstovsek S. Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Samra B, Richard-Carpentier G, Ravandi F, Kadia T, Guerra V, Daver N, DiNardo C, Issa G, Bose P, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Short N. Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Yilmaz M, Kantarjian H, Wang X, Khoury J, Ravandi F, Jorgensen J, Short N, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Sasaki K, Kantarjian H, Samra B, Short N, Khoury J, Kanagal-Shamanna R, Konopleva M, Jain N, DiNardo C, Khouri R, Garcia-Manero G, Kadia T, Wierda W, Tippett N, Garris R, Jeanis V, Daver N, Thompson P, Yilmaz M, Cortes J, O'Brien S, Ravandi F, Jabbour E. Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Short N, Kantarjian H, Ravandi F, Huang X, Jain N, Sasaki K, Khouri R, Daver N, Pemmaraju N, Khoury J, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Borthakur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Rostykus M, Garris R, Ward M, Huang B, Encarnacion C, Loiselle C, O'Brien S, Jabbour E. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Alfayez M, Kadia T, Konopleva M, Ravandi F, Jabbour E, Garcia-Manero G, Pierce S, Yilmaz M, Short N, Cortes J, Shoukier M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian H, DiNardo C, Daver N. Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm). Blood (ASH Annual Meeting) 134(Suppl 1), 2019. e-Pub 2019.
Yilmaz M, Kantarjian H, Ravandi F, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes J, Short N, Sasaki K, Issa G, Koller P, Schroeder H, Kadia T, Verstovsek S, Daver N, Jain N, Konopleva M, O’Brien S, Jabbour E. Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia 19(S1):S185, 2019. e-Pub 2019.
Sasaki K, Kantarjian H, Richard-Carpentier G, Short N, Ravandi F, Khouri M, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Issa G, Jacob J, Garris R, Yilmaz M, Thompson P, Nasnas P, Pemmaraju N, Cortes J, O’Brien S, Jabbour E. Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Clinical Lymphoma Myeloma and Leukemia 19(S1):S181-S181, 2019. e-Pub 2019.
Naqvi K, Jabbour E, Skinner J, Anderson K, Yilmaz M, Jain N, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Takahashi K, Burger J, Borthakur G, Estrov Z, Pemmaraju N, Paul S, Dellasala S, Cortes J, Kantarjian H. Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP). Journal of Clinical Oncology 37(15, S1), 2019. e-Pub 2019.
Bose P, MD, McCue D, Wiederhold NP, PharmD, Kadia TM, MD, Borthakur G, MD, Ravandi F, MBBS, Yilmaz M, MD, Takahashi K, MD, Thompson PA, MBBS, Pemmaraju N, MD, Daver NG, MD, Burger JA, MD, PhD, ECortes J, MD, Garcia-Manero G, MD, Verstovsek S, MD, PhD, Konopleva MY, MD, PhD, Jain N, MD, DiNardo CD, MD, MSc, Alvarado Y, MD, Naqvi K, MD, MPH, Kornblau SM, MD, Ferrajoli A, MD, Wierda WG, MD, PhD, Estrov ZE, MD, Benton CB, MD, Masarova L, MD, Montalban-Bravo G, MD, Sasaki K, MD, Rausch CR, PharmD, KayleighMarx, PharmD, Qiao W, PhD, Huang X, PhD, Bivins CA, RN, Pierce SA, BSN, BA, Kantarjian HM, MD, PKontoyiannis D, MD. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood, 2018. e-Pub 2018.
Short NJ, MD, Jabbour EJ, MD, Ravandi F, MBBS, Huang X, PhD, Jain N, MD, Sasaki K, MD, Pemmaraju N, MD, Daver NG, MD, Khoury JD, MD, Jorgensen JL, MD, PhD, Alvarado Y, MD, Konopleva MY, MD, PhD, Garcia-Manero G, MD, Kadia TM, MD, Yilmaz M, MD, Borthakur G, MD, Burger JA, MD, PhD, Kornblau SM, MD, Wierda WG, MD, PhD, DiNardo CD, MD, MSc, Ferrajoli A, MD, Nasnas P, MD, Jacob J, RN, Garris RE, MSc, MO'Brien S, MD, Kantarjian HM, MD. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 132(Suppl 1), 2018. e-Pub 2018.
Yalniz F, Kantarjian HM, MD, Kadia TM, MD, Garcia-Manero G, MD, Patel K, MD, PhD, Loghavi S, MD, Sasaki K, MD, Daver NG, MD, DiNardo CD, MD, MSc, Pemmaraju N, MD, Short NJ, MD, Yilmaz M, MD, Bose P, MD, Naqvi K, MD, MPH, Pierce SA, BSN, BA, Cortes JE, MD, Ravandi F. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood 132(Suppl 1), 2018. e-Pub 2018.
Sasaki K, MD, Kanagal-Shamanna R, MD, Montalban-Bravo G, MD, Assi R, MD, Naqvi K, MD, MPH, Pierola AA, MD, PhD, Yilmaz M, MD, Short NJ, MD, Jabbour EJ, MD, Ravandi F, MBBS, Kadia TM, MD, Pierce SA, BSN, BA, KoichiTakahashi, MD, DiNardo CD, MD, MSc, Nogueras González GM, MPH, Abaza Y, MD, KC Devendra KC, MD, Chamoun K, MD, Sakurai K, MD, Patel KP, MBBS, PhD, Cortes JE, MD, Kantarjian HM, MD, Garcia-Manero G, MD. The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood 132(Suppl 1), 2018. e-Pub 2018.
Borthakur G, MD, Cortes JE, MD, Garcia-Manero G, MD, Patel K, MD, PhD, Ravandi F, MBBS, Kadia TM, MD, Pemmaraju N, MD, Daver NG, MD, Yilmaz M, MD, Estrov ZE, MD, Ohanian MN, DO, Maduike R, Kantarjian HM, MD. Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia. Blood 132(Suppl 1), 2018. e-Pub 2018.
Kadia TM, MD, Konopleva MY, MD, PhD, Garcia-Manero G, MD, Benton CB, MD, Wierda WG, MD, PhD, Bose P, MD, Yilmaz M, MD, Jabbour EJ, MD, Kornblau SM, MD, Bhalla KN, MD, Pemmaraju N, MD, Jain N, MD, Malla R, RN, BSN, Borthakur G, MD, Cortes JE, MD, Ravandi F, MBBS, Kantarjian HM, MD. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood (ASH Annual Meeting) 132(Suppl 1), 2018. e-Pub 2018.
Chamoun K, Kantarjian HM, Naqvi K, Wang X, Garcia-Manero G, Borthakur G, Jabbour EJ, Kadia TM, Daver NG, DiNardo CD, Jain N, Konopleva MY, Cortes J, Ravandi F, Yilmaz M. Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL). Blood (ASH Annual Meeting) 132(Suppl 1), 2018. e-Pub 2018.
Assi R, Boddu P, Kadia TM, Estrov ZE, Garcia-Manero G, Ravandi F, Jabbour EJ, Takahashi K, Konopleva MY, PhD, Andreeff M, Zahr AA, DiNardo CD, Borthakur G, Jain N, Pemmaraju N, Yilmaz M, Short NJ, Ning J, Pierce SA, Wierda WG, Cortes JE, Kantarjian HM, Daver NG. Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis(M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts. Blood (ASH Annual Meeting) 132(Suppl 1), 2018. e-Pub 2018.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, KoichiTakahashi, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian MN, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, GWierda W. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting) 36(Suppl 1), 2018. e-Pub 2018.
Alfayez M, MD, Kantarjian HM, MD, Ravandi F, MBBS, Konopleva MY, MD, PhD, Garcia-Manero G, MD, MKadia T, MD, Jabbour EJ, MD, Borthakur G, MD, DiNardo CD, MD, MSc, Estrov ZE, MD, Pemmaraju N, MD, APierce S, BSN, BA, Yilmaz M, MD, Short NJ, MD, Takahashi K, MD, Assi R, MD, Andreeff M, MD, PhD, Cortes JE, MD, Daver NG, MD. Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts)Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. Blood (ASH Annual Meeting) 132(Suppl 1), 2018. e-Pub 2018.
Alfayez M, MD, Kantarjian HM, MD, Ravandi F, MBBS, Garcia-Manero G, MD, Konopleva MY, MD, PhD, GDaver N, MD, DiNardo CD, MD, MSc, Borthakur G, MD, Bose P, MD, Andreeff M, MD, PhD, Alvarado Y, MD, Yilmaz M, MD, Pemmaraju N, MD, Kornblau SM, MD, Estrov ZE, MD, Benton CB, MD, Takahashi K, MD, Naqvi K, MD, MPH, Slack R, MS, Islam R, MD, Jabbour EJ, MD, Cortes JE, MD, Kadia TM, MD. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood (ASH Annual Meeting) 132(Suppl 1), 2018. e-Pub 2018.
Rausch CR, Paul S, Kantarjian HM, Ravandi F, Short NJ, Sasaki K, Khouri M, Jacob J, Montalbano KS, Thompson PA, Jain N, Yilmaz M, Naqvi K, Ohanian M, Nasnas P, Estrov ZE, O'Brien SM, Jabbour EJ. Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. Blood (ASH Annual Meeting) 132(Suppl 1), 2018. e-Pub 2018.
KojiSasaki, MD, Kantarjian HM, MD, Short NJ, MD, Ravandi F, MBBS, Khouri M, Garcia-Manero G, MD, GDaver N, MD, Kadia TM, MD, Konopleva MY, MD, PhD, Jain N, MD, Issa GC, MD, Jacob J, RN, Garris RE, MSc, Yilmaz M, MD, Thompson PA, MBBS, Nasnas P, MD, Pemmaraju N, MD, Cortes JE, MD, O'Brien SM, MD, JJabbour E, MD. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood (ASH Annual Meeting) 132(Suppl 1), 2018. e-Pub 2018.
Naqvi K, MD, MPH, Sasaki K, MD, Montalban-Bravo G, MD, Alfonso A, MD, Yilmaz M, MD, Short NJ, MD, Assi R, MD, Jabbour EJ, MD, Ravandi F, MBBS, Kadia TM, MD, Pierce SA, BSN, BA, Takahashi K, MD, Nogueras González GM, MPH, Kanagal-Shamanna R, MD, Patel KP, MBBS, PhD, Kantarjian HM, MD, Garcia-Manero G, MD. Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 132(Supple 1), 2018. e-Pub 2018.
Strati P, Garcia-Manero G, Kadia TM, Borthakur G, Konopleva M, Daver NG, Dinardo CD, Short NJ, Yilmaz M, Naqvi K, Pierce S, Cortes JE, Kantarjian HM, Ravandi F. Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts. Journal of Clinical Oncology (ASCO) 36(Suppl 15), 2018. e-Pub 2018.
Yilmaz M, Wang F, Loghavi S, BuesoRamos CE, Gumbs C, Little L, Song X, Zhang J, Kadia TM, Borthakur G, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM, Futreal PA, Takahashi K, Ravandi F, Short NJ. Clonal evolution in acute myeloid leukemia (AML): Relapse after a long remission period. Journal of Clinical Oncology (ASCO) 36(Suppl 15), 2018. e-Pub 2018.
Boddu P, Kadia TM, Garcia-Manero G, Cortes JE, Borthakur G, Konopleva M, Jabbour E, Daver NG, Dinardo CD, Naqvi K, Yilmaz M, Short NJ, Nogueras-Gonzalez GM, Pierce S, Kantarjian HM, Ravandi F. Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML. JCO 36(Suppl 15), 2018. e-Pub 2018.
Assi RE, Albitar M, Ma W, Patel K, Takahashi K, Yilmaz M, Short NJ, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi F. Comparison of somatic mutations profiles from next-generation sequencing (NGS) of cell-free DNA (cfDNA) versus bone marrow (BM) in acute myeloid leukemia (AML). JCO 36(Suppl 15), 2018. e-Pub 2018.
Ghorab A, Kantarjian HM, Jain P, Kanagal-Shamanna R, Jabbour E, Sasaki K, Kadia TM, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. JCO 36(Suppl 15), 2018. e-Pub 2018.
Bazarbachi AH, Yilmaz M, Ravandi F, Thomas DA, Khouri M, GarciaManero G, Garris RS, Cortes JE, Short NJ, Sasaki K, Issa GC, Koller PB, Kadia TM, Verstovsek S, Daver NG, Jain N, Konopleva M, O'Brien SM, Jabbour E, Kantarjian HM. A phase 2 study of hyper-CVAD plus ofatumumab as front line therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results. Journal of Clinical Oncology (ASCO) 36(Suppl 15), 2018. e-Pub 2018.
Yilmaz M, Devendra KC, Akosile MA, Khoury JD, Short NJ, Cortes JE, Garcia-Manero G, Ravandi F, Kadia T, Sasaki K, Konopleva M, Wierda WG, Jain N, Verstovsek S, Estrov Z, Pierce S, O'Brien SM, Jabbour EJ, Kantarjian HM. The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130(Suppl 1):2712, 2017. e-Pub 2017.
Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Khoury JD, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Khouri M, Jain N, Verstovsek S, Estrov Z, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130(Suppl 1):1434, 2017. e-Pub 2017.
Yilmaz M, Kantarjian HM, Wang X, Devendra KC, Khoury JD, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda WG, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130(Suppl 1):1435, 2017. e-Pub 2017.
Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ, Wierda WG. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood 130(Suppl 1):429, 2017. e-Pub 2017.
Naqvi K, Bravo GM, Pierola AA, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Kadia T, Pierce S, Borthakur G, Daver N, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, González GN, Kantarjian HM, Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential — Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 130(Suppl 1):4258, 2017. e-Pub 2017.
Jain N, Cortes JE, Ravandi F, Konopleva M, Alvarado Y, Kadia T, Wierda WG, Borthakur G, Naqvi K, Pemmaraju N, DiNardo CD, Daver N, Yilmaz M, Patel K, Linderman DB, Garris R, Jabbour EJ, Kantarjian HM. Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase. Blood 130(Suppl 1):143, 2017. e-Pub 2017.
Bose P, Pemmaraju N, Schroeder K, Ferrajoli A, Jabbour EJ, Daver N, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF). Blood 130(Suppl 1):1632, 2017. e-Pub 2017.
Ghorab A, Jain P, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. Blood 130(Suppl 1):2868, 2017. e-Pub 2017.
Khan M, DiNardo CD, Milton DR, Yilmaz M, Cortes JE, Kantarjian HM, Lichtiger B, Aung FM. Post-Transfusion Overall Survival for HLA- Alloimmunized Platelet Refractorythrombocytopenic Leukemia Patients. Blood 130(Suppl 1):4924, 2017. e-Pub 2017.
Short N, Kantarjian H, Ravandi F, Daver N, Pemmaraju N, Thomas D, Yilmaz M, Kadia T, Sasaki K, Garris R, Garcia-Manero G, DiNardo C, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, O'Brien S, Jabbour E. UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. Haematologica 102(S2):198, 2017. e-Pub 2017.
Short NJ, Kantarjian HM, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, Yilmaz M, Kadia TM, Sasaki K, Garris R, Garcia-Manero G, Dinardo CD, Konopleva M, Estrov Z, Jain N, Wierda WG, Jeanis V, Cortes JE, O'Brien SM, Jabbour E. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. JCO 35(Suppl 15), 2017. e-Pub 2017.
Sasaki K, Jabbour EJ, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, Khouri RB, Yilmaz M, Kadia TM, Short NJ, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda WG, Jeanis TV, Cortes JE, O'Brien SM, Kantarjian HM. Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Blood 128(22), 2016. e-Pub 2016.
Koji S, Jabbour EJ, O'Brien S, Thomas D, Ravandi F, Garcia-Manero G, Cortes J, Short N, Verstovsek S, Yilmaz M, Wierda W, Borthakur G, Kadia T, Konopleva M, Khouri M, Ferrajoli A, Daver N, Pemmaraju N, DiNardo C, Jain N, Benton C, Takahashi K, Naqvi K, Bose P, Kornblau S, Andreeff M, Keating M, Freireich E, Kantarjian H. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood 128(22), 2016. e-Pub 2016.
Short N, Kantarjian H, Jorgensen J, Ravandi F, Yilmaz M, Khouri M, Wang S, Thomas D, Khoury J, Champlin R, Khouri I, Kebriaei P, Marin D, O'Brien S, Garcia-Manero G, Cortes J, Sasaki K, DiNardo C, Kadia T, Jain N, Konopleva M, Garris R, Jabbour E. Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. Blood 128(22), 2016. e-Pub 2016.
Sasaki K, O'Brien S, Ravandi F, Thomas D, Moore HG, Cortes J, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jeanis V, Borthakur G, Wierda W, Ferrajoli A, Kantarjian H, Jabbour E. Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute lymphoblastic Leukemia (Ph-positive ALL). Clinical Lymphoma, Myeloma and Leukemia 15(Supplement 2):S5, 2015. e-Pub 2015.
Sasaki K, Yilmaz M, Kantarjian H, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes J, Schroeder H, Kadia T, Ravandi F, Verstovsek S, Daver N, Jain N, Konopleva M, O'Brien S, Jabbour E. Ofatumumab in Combination with Hyper-CVAD Regimen as Frontline Treatment for Adults with CD-20 Positive Acute Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 15(Supplement 1):S18, 2015. e-Pub 2015.
Yilmaz M, Sasaki K, Ravandi F, Cortes J, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Borthakur G, Dinardo C, Takahashi K, O'Brien S, Estrov Z, Pike A, Brandt M, Kantarjian H, Jabbour E. Randomized Phase II Study of Clofarabine or Fludarabine Combined with ldarubicin and Cytarabine for the Treatment of Newly Diagnosed AML. Clinical Lymphoma, Myeloma and Leukemia 15(Supplement 2):S18, 2015. e-Pub 2015.
Sasaki K, Jabbour E, Thomas D, Khouri M, Yilmaz M, Garcia-Manero G, Ravandi F. Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic leukemia: A Result of a Phase II Clinical Trial. Blood 126(23), 2015. e-Pub 2015.
Yilmaz M, Kantarjian H, Ravandi F, Jorgensen J, Wang S, Garcia-Manero G, Cortes J, Sasaki. The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Beel/ Acute Lymphoblastic Leukemia (ALL). Blood 126(23), 2015. e-Pub 2015.
Yilmaz M, Kantarjian H, Cortes J, Garcia-Manero G, Chahoud J, Ravandi F, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierces, Jabbour E. Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood 126(23), 2015. e-Pub 2015.
Dahl J, Kantarjian H, Yilmaz M, Kadia T, Garcia-Manero G, Ravandi F, Borthakur G, Cortes J, Ferrajoli A, Sasaki K, Chahoud J, Autry J, Garris R, Jabbour E. Outcomes of Patients with Relapsed/Refractory (R/R) 8-ce/l Acute lymphocytic leukemia (All} post Blinatumomab Failure. Blood 126(23), 2015. e-Pub 2015.
Sasaki K, O'Brien S, Ravandi F, Thomas D, Moore HG, Cortes J, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jean is V, Chaoud J, Borthakur G, Wierda W, Ferrajoli A, Kantarjian H, Jabbour E. Frontline Hyper-CVAD with Ponatinib for Patients {pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase 11 Study. Blood 126(23), 2015. e-Pub 2015.
Gulbis A, Yilmaz M, Sui D, Bassett R, Rivera Z, Champlin RR, De-Lima M. Linezolid Use Early After Stem Cell Transplant - A Cautionary Tale. Biology of Blood and Marrow Transplantation 19(2):S376-S377, 2013. e-Pub 2013.
Yilmaz M, Kantarjian H, Quintas-Cardama A, O'Brien S, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Cortes J. Estimated Glomerular Filtration Rate Changes in Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors. Blood 122, 2013. e-Pub 2013.
Gulbis AM, Yilmaz M, Sui D, Bassett RL, Rivera ZR, Champlin RE, Lima MD. Linezolid Use in Hematopoietic Stem Cell Transplantation: A Cautionary Tale. Blood 120(21), 2012. e-Pub 2012.
Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. The outcome of patients (pts) with chronic myeloid leukemia (CML) treated with imatinib outside of a clinical trial or on a clinical trial at a single institution. Blood 120, 2012. e-Pub 2012.
Yilmaz M, Han X, De-lima M, Hosing C, Popat, U, Champlin R, Qazilbash M. Incidence and Outcome of Adenovirus Infection in Adult Allogeneic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation 17(2):S290, 2011. e-Pub 2011.
Agaoglu, N, Baykan, 0, Orak, N, Arikan, S, Aksoy, C, Yilmaz, M, Agirbasli, M. Dietary, physical activity and anthropometric variables in low to middle socioeconomic status children and adolescents from Istanbul, Turkey. Atherosclerosis Supplements 9(1):254, 2008. e-Pub 2008.

Book Chapters

Yilmaz M, Udden M. Acute Lymphoblastic Leukemia. In: Tumor Board Review, Guidelines and Case Reviews in Oncology. second. Demos Medical, 348-356, 2015.

Letters to the Editor

Marvin-Peek, J, Kantarjian, HM, Jen, WY, Daver, N, Short, NJ, Borthakur, G, Bazinet, A, Maiti, A, Abbas, HA, Yilmaz, M, Issa, GC, Macfarland, M, Alvarado, Y, Garcia-Manero, G, Alousi, AM, Popat, UR, Shpall, E, Ravandi-Kashani, F, DiNardo, C, Kadia, TM. Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML. American journal of hematology 101: 917-922, 2026.
Marvin-Peek J, Kantarjian H, Jen WY, Daver N, Short N, Borthakur G, Bazinet A, Maiti A, Abbas H, Yilmaz M, Issa G, Macfarland M, Alvarado Y, Garcia-Manero G, Alousi A, Popat U, Shpall E, Ravandi F, DiNardo C, Kadia TM. Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML. Am J Hematol 101: 917-922, 2026.
Azevedo, RS, Wang, S, Swanson, DM, Daver, N, Pemmaraju, N, Kadia, TM, Issa, GC, Yilmaz, M, Borthakur, G, Senapati, J, Jen, WY, Short, NJ, Ravandi-Kashani, F, Wang, W, Fang, H, Xu, J, Patel, KP, Tang, G, Medeiros, LJ, DiNardo, C, Loghavi, S. CD123 expression and its correlation with mutation profile in acute myeloid leukaemia. British Journal of Haematology 207: 1648-1652, 2025.
Arora S, Loghavi S, Daver N, Ravandi F, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Yilmaz M, Issa GC, McCormack J, Karrar O, Pierce S, Kantarjian H, Short NJ. Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AML. Am J Hematol 100: 2155-2159, 2025.
Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver N, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol 99: 1434-1436, 2024.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
Fernando RR, Yilmaz M, Higgins JP. The changing electrocardiogram in Brugada syndrome. Int J Cardiol 163: e36-7, 2013.

Less

CV information above last modified July 21, 2026

Musa Yilmaz, MD

About Dr. Musa Yilmaz

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Musa Yilmaz, MD

About Dr. Musa Yilmaz

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson